News

July 27, 2017

BACKGROUND: Inhibition of the hedgehog signaling pathway (HHSP) for the treatment of locally advanced basal cell carcinoma (BCC) and metastatic BCC (mBCC) has produced promising results. Typically, mBCC is not taken into consideration during the workup of a patient with multifocal metastatic disease who has a history of BCC. The objective of... full article

July 27, 2017

Abstract
The use of 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) in subjects with advanced basal cell carcinoma (BCC) has not been fully explored due to the rarity of disease presentation. This study evaluated PET/CTs from subjects with advanced BCC participating in a phase I dose-escalation... full article

July 27, 2017

To read more click here

Weiss G.J. and Korn R.L. “Interpretation of PET Scans: Do Not Take SUVs at Face Value.” J Thor Onc., 7(12): 1744-45, (2012).

July 27, 2017

Abstract
Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are... full article

August 02, 2016

Dr. Ron Korn involved in study published to PubMed.
Abstract
PURPOSE:
To evaluate the feasibility of constructing radiogenomic-based... full article

May 04, 2016

Imaging to Cure Cancer: Valuable Contribution of Radiology for Clinical Trial Success
Written by Dr. Ron Korn, Founder, Chairman and Chief Medical Officer at Imaging Endpoints

“I keep dreaming of a future, a future with a long and healthy life, not lived in the shadow of cancer but in the... full article

April 06, 2016

11th Annual TOP Conference – Don’t Forget Clinical Trials

Imaging Endpoints CMO and Founder, Ronald Korn, MD., Ph.D. presents “New Imaging Techniques to Aid Creative Clinical Trial Designs.” ... full article

March 03, 2016

Dr. Ron Korn, founder and Chief Medical Officer of Imaging Endpoints Core Lab will be a featured speaker at the Cancer Treatment Centers of America® (CTCA) Western Regional Medical Center (Western) Annual New Treatments in Oncology (ANTO) conference. This conference focuses on advances in cancer research, new treatments and patient care. 

Pages